文献速递精神分裂症与精神病性障碍

临床高危精神病心理测量工具预后准确性与临床效用的系统综述与荟萃分析

Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.
PubMed 文献 · Mol Psychiatry · 2022-06-03

在临床样本中,CHR-P工具预后准确性优异(AUC=0.85),敏感性高(0.93)但特异性差(0.58),CHR-P+的阳性似然比小(2.17),CHR-P-的阴性似然比大(0.11),支持在临床样本中使用心理测量工具进行精神病一级指示性预防。

要点

  • 临床样本中CHR-P心理测量工具预后准确性优异(AUC=0.85)。
  • 敏感性高(0.93)但特异性差(0.58)。
  • CHR-P+阳性似然比小(2.17),CHR-P-阴性似然比大(0.11)。

核心结论

  • 这些发现巩固了在临床样本中使用心理测量工具进行CHR-P精神病一级指示性预防。
  • 未来研究应提高识别精神病风险的能力。

研究设计与样本

  • 系统综述与荟萃分析,检索Web of Knowledge数据库至2022年1月1日,纳入纵向研究。
  • 预后准确性通过AUC、敏感性和特异性评估,临床效用分析包括似然比、Fagan列线图和人群归因分数(PAF)。

主要发现

  • 临床样本中CHR-P心理测量工具的预后准确性优异:AUC=0.85(95%CI: 0.81-0.88),平均随访时间34个月。
  • 敏感性 outstanding(0.93,95%CI: 0.87-0.96),特异性差(0.58,95%CI: 0.50-0.66)。
  • CHR-P+与发生精神病的阳性似然比LR+小(2.17,95%CI: 1.81-2.60)相关。
  • CHR-P-与发生精神病的阴性似然比LR-大(0.11,95%CI: 0.06-0.21)相关。
  • 非临床一般人群样本中,Fagan列线图显示阳性后验风险低(0.0017%),阴性后验风险低(0.0001%)。

关键数值与推荐

  • 临床样本中CHR-P心理测量工具预后准确性AUC=0.85(95%CI: 0.81-0.88)。
  • 敏感性0.93(95%CI: 0.87-0.96),特异性0.58(95%CI: 0.50-0.66)。
  • LR+为2.17(95%CI: 1.81-2.60),LR-为0.11(95%CI: 0.06-0.21)。
  • PAF为10.9%(95%CI: 4.1-25.5%)。

临床怎么用

  • 在临床样本中,CHR-P心理测量工具可用于精神病的一级指示性预防。
  • 非临床一般人群样本中,Fagan列线图显示阳性后验风险低(0.0017%),阴性后验风险低(0.0001%)。

局限性

  • 关于CHR-P诊断标准(DSM-5 attenuated psychosis syndrome)或非临床样本的可荟萃分析研究不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate prognostication of individuals at clinical high-risk for psychosis (CHR-P) is an essential initial step for effective primary indicated prevention. We aimed to summarise the prognostic accuracy and clinical utility of CHR-P assessments for primary indicated psychosis prevention. Web of Knowledge databases were searched until 1st January 2022 for longitudinal studies following-up individuals undergoing a psychometric or diagnostic CHR-P assessment, reporting transition to psychotic disorders in both those who meet CHR-P criteria (CHR-P + ) or not (CHR-P-). Prognostic accuracy meta-analysis was conducted following relevant guidelines. Primary outcome was prognostic accuracy, indexed by area-under-the-curve (AUC), sensitivity and specificity, estimated by the number of true positives, false positives, false negatives and true negatives at the longest available follow-up time. Clinical utility analyses included: likelihood ratios, Fagan's nomogram, and population-level preventive capacity (Population Attributable Fraction, PAF). A total of 22 studies (n = 4 966, 47.5% female, age range 12-40) were included. There were not enough meta-analysable studies on CHR-P diagnostic criteria (DSM-5 Attenuated Psychosis Syndrome) or non-clinical samples. Prognostic accuracy of CHR-P psychometric instruments in clinical samples (individuals referred to CHR-P services or diagnosed with 22q.11.2 deletion syndrome) was excellent: AUC = 0.85 (95% CI: 0.81-0.88) at a mean follow-up time of 34 months. This result was driven by outstanding sensitivity (0.93, 95% CI: 0.87-0.96) and poor specificity (0.58, 95% CI: 0.50-0.66). Being CHR-P + was associated with a small likelihood ratio LR + (2.17, 95% CI: 1.81-2.60) for developing psychosis. Being CHR-P- was associated with a large LR- (0.11, 95%CI: 0.06-0.21) for developing psychosis. Fagan's nomogram indicated a low positive (0.0017%) and negative (0.0001%) post-test risk in non-clinical general population samples. The PAF of the CHR-P state is 10.9% (95% CI: 4.1-25.5%). These findings consolidate the use of psychometric instruments for CHR-P in clinical samples for primary indicated prevention of psychosis. Future research should improve the ability to rule in psychosis risk.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Oliver D, Arribas M, Radua J, et al. Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. Mol Psychiatry. 2022. PMID: 35665763. doi:10.1038/s41380-022-01611-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。